the primary autoimmune neutropenia mediated by autoantibodies against mature neutrophils and/or their bone marrow progenitor/precursor cells; and second, the previously named chronic idiopathic ...

Pivotal Phase 3 4WARD clinical trial is evaluating use of oral mavorixafor as monotherapy and in combination with injectable ...

X4 Pharmaceuticals (XFOR) announced its upcoming presentations at the 66th American Society of Hematology Annual Meeting and Exposition, ...

Positive Results from Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia On November 13, 2024, X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) announced positive topline results from the Phase 2 ...

“Since the U.S. approval of G-CSF to treat severe chronic neutropenia, there has remained a significant unmet need for an optimal treatment in terms of long-term efficacy, safety, and route of ...

Detailed price information for X4 Pharmaceuticals Inc (XFOR-Q) from The Globe and Mail including charting and trades.

The condition can increase the risk of infections. Neutropenia or low levels of neutrophils, primarily results from chemotherapy. It could also result from conditions that disrupt normal ...

Mavorixafor durably and meaningfully elevated participants’ mean absolute neutrophil counts (ANC) Mavorixafor enabled substantial reductions in G-CSF dosing while maintaining mean ANC at normal ...